Edition:
United States

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

9.56USD
23 Feb 2018
Change (% chg)

$-0.71 (-6.91%)
Prev Close
$10.27
Open
$10.47
Day's High
$10.50
Day's Low
$9.21
Volume
82,182
Avg. Vol
42,217
52-wk High
$10.80
52-wk Low
$5.45

Chart for

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $466.21
Shares Outstanding(Mil.): 48.77
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Chemocentryx Secures Up To $100 Million In New Capital Commitments

* CHEMOCENTRYX SECURES UP TO $100 MILLION IN NEW CAPITAL COMMITMENTS

Jan 04 2018

BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review

* AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

Jan 04 2018

BRIEF-Chemocentryx reports Q3 revenue $9.0 million

* Chemocentryx reports third quarter 2017 financial results and recent highlights

Nov 07 2017

Competitors

Earnings vs. Estimates